Johnson & Johnson Property, Plant, and Equipment 2012-2026 | JNJ
Johnson & Johnson property, plant, and equipment from 2012 to 2026. Property, plant, and equipment can be defined as the sum of all net property, plant & Equipment fields. Where companies do not report a break down of plant, property, & equipment, the value is entered in this field alone.
- Johnson & Johnson property, plant, and equipment for the quarter ending March 31, 2026 was $23.169B, a 12.92% increase year-over-year.
- Johnson & Johnson property, plant, and equipment for 2025 was $23.169B, a 12.92% increase from 2024.
- Johnson & Johnson property, plant, and equipment for 2024 was $20.518B, a 3.12% increase from 2023.
- Johnson & Johnson property, plant, and equipment for 2023 was $19.898B, a 10.66% increase from 2022.
|
Johnson & Johnson Annual Property, Plant, and Equipment (Millions of US $) |
|
|---|---|
| 2025 | $23,169 |
| 2024 | $20,518 |
| 2023 | $19,898 |
| 2022 | $17,982 |
| 2021 | $18,962 |
| 2020 | $18,766 |
| 2019 | $17,658 |
| 2018 | $17,035 |
| 2017 | $17,005 |
| 2016 | $15,912 |
| 2015 | $15,905 |
| 2014 | $16,126 |
| 2013 | $16,710 |
| 2012 | $16,097 |
| 2011 | $14,739 |
|
Johnson & Johnson Quarterly Property, Plant, and Equipment (Millions of US $) |
|
|---|---|
| 2025-12-31 | $23,169 |
| 2025-09-30 | $22,338 |
| 2025-06-30 | $21,949 |
| 2025-03-31 | $20,871 |
| 2024-12-31 | $20,518 |
| 2024-09-30 | $20,479 |
| 2024-06-30 | $19,748 |
| 2024-03-31 | $19,632 |
| 2023-12-31 | $19,898 |
| 2023-09-30 | $18,821 |
| 2023-06-30 | $20,576 |
| 2023-03-31 | $20,174 |
| 2022-12-31 | $17,982 |
| 2022-09-30 | $18,152 |
| 2022-06-30 | $18,354 |
| 2022-03-31 | $18,701 |
| 2021-12-31 | $18,962 |
| 2021-09-30 | $18,478 |
| 2021-06-30 | $18,632 |
| 2021-03-31 | $18,367 |
| 2020-12-31 | $18,766 |
| 2020-09-30 | $17,855 |
| 2020-06-30 | $17,598 |
| 2020-03-31 | $17,401 |
| 2019-12-31 | $17,658 |
| 2019-09-30 | $17,048 |
| 2019-06-30 | $17,248 |
| 2019-03-31 | $17,000 |
| 2018-12-31 | $17,035 |
| 2018-09-30 | $16,629 |
| 2018-06-30 | $16,632 |
| 2018-03-31 | $17,040 |
| 2017-12-31 | $17,005 |
| 2017-09-30 | $16,628 |
| 2017-06-30 | $16,458 |
| 2017-03-31 | $16,191 |
| 2016-12-31 | $15,912 |
| 2016-09-30 | $16,095 |
| 2016-06-30 | $15,972 |
| 2016-03-31 | $15,964 |
| 2015-12-31 | $15,905 |
| 2015-09-30 | $15,551 |
| 2015-06-30 | $15,583 |
| 2015-03-31 | $15,364 |
| 2014-12-31 | $16,126 |
| 2014-09-30 | $15,804 |
| 2014-06-30 | $16,155 |
| 2014-03-31 | $15,996 |
| 2013-12-31 | $16,710 |
| 2013-09-30 | $16,127 |
| 2013-06-30 | $15,794 |
| 2013-03-31 | $15,721 |
| 2012-12-31 | $16,097 |
| 2012-09-30 | $15,845 |
| 2012-06-30 | $15,622 |
| 2012-03-31 | $14,824 |
| 2011-12-31 | $14,739 |
| 2011-09-30 | $14,635 |
| 2011-06-30 | $14,974 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Large Cap Pharmaceutical | $574.358B | $94.193B |
| Johnson & Johnson's biggest strength is its diversified business model. It operates through pharmaceuticals, medical devices and consumer products divisions. Its diversification helps it to withstand economic cycles more effectively. J&J has one of the largest research and development (R&D) budget among pharma companies. J&J's worldwide business is divided into three segments: Pharmaceutical, Medical Devices and Consumer. The company has several drugs covering a broad range of areas such as neuroscience, cardiovascular & metabolism, immunology, oncology, pulmonary hypertension and infectious diseases and vaccines. The Medical Devices Segment offers products in the orthopedics, surgery, interventional solutions and vision markets. The Consumer Segment segment includes a broad range of products covering the areas of baby care, beauty/skin health, oral care, wound care and womens' health care, as well as over-the-counter (OTC) pharmaceutical products. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Eli Lilly (LLY) | United States | $887.629B | 38.81 |
| AbbVie (ABBV) | United States | $367.673B | 20.79 |
| Roche Holding AG (RHHBY) | Switzerland | $318.782B | 0.00 |
| Merck (MRK) | United States | $299.893B | 13.54 |
| Novartis AG (NVS) | Switzerland | $293.951B | 17.16 |
| Novo Nordisk (NVO) | Denmark | $167.527B | 9.60 |
| Pfizer (PFE) | United States | $153.074B | 8.33 |
| Sanofi (SNY) | France | $114.048B | 10.56 |
| Bayer (BAYRY) | Germany | $46.178B | 8.70 |
| Innoviva (INVA) | United States | $1.760B | 5.88 |